Tectonic Therapeutic, Inc. (TECX) stock
TECXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$20.98−0.16 (-0.76%)
Close on Nov 16, 2026Market cap $410.15MP/E –Yield 0.00%
Tectonic Therapeutic operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Tectonic Therapeutic's operating income for the twelve months ending Jun 30, 2026 was -$94.93M. For fiscal 2025 it was -$84.04M. The highest annual figure on record is -$18.39M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$84.04M | – |
| FY2024 | Dec 31, 2024 | -$58.02M | – |
| FY2023 | Dec 31, 2023 | -$44.65M | – |
| FY2022 | Dec 31, 2022 | -$105.43M | – |
| FY2021 | Dec 31, 2021 | -$118.84M | – |
| FY2020 | Dec 31, 2020 | -$120.23M | – |
| FY2019 | Dec 31, 2019 | -$75.81M | – |
| FY2018 | Dec 31, 2018 | -$46.24M | – |
| FY2017 | Dec 31, 2017 | -$18.39M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$24.22M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.30M | – |
| Q4 FY2025 | Dec 31, 2025 | -$21.52M | – |
| Q3 FY2025 | Sep 30, 2025 | -$21.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$22.33M | – |
| Q1 FY2025 | Mar 31, 2025 | -$18.30M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.99M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.64M | – |
| Q2 FY2024 | Jun 30, 2024 | -$11.42M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.97M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.37M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.11M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.63M | – |
| Q1 FY2023 | Mar 31, 2023 | -$25.22M | – |
| Q4 FY2022 | Dec 31, 2022 | -$25.26M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.99M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.77M | – |
| Q1 FY2022 | Mar 31, 2022 | -$29.42M | – |
| Q4 FY2021 | Dec 31, 2021 | -$27.96M | – |
| Q3 FY2021 | Sep 30, 2021 | -$32.62M | – |
| Q2 FY2021 | Jun 30, 2021 | -$31.38M | – |
| Q1 FY2021 | Mar 31, 2021 | -$26.88M | – |
| Q4 FY2020 | Dec 31, 2020 | -$28.06M | – |
| Q3 FY2020 | Sep 30, 2020 | -$36.72M | – |
| Q2 FY2020 | Jun 30, 2020 | -$28.86M | – |
| Q1 FY2020 | Mar 31, 2020 | -$26.59M | – |
| Q4 FY2019 | Dec 31, 2019 | -$23.43M | – |
| Q3 FY2019 | Sep 30, 2019 | -$18.06M | – |
| Q2 FY2019 | Jun 30, 2019 | -$16.61M | – |
| Q1 FY2019 | Mar 31, 2019 | -$17.70M | – |
| Q4 FY2018 | Dec 31, 2018 | -$16.68M | – |
| Q3 FY2018 | Sep 30, 2018 | -$12.23M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.55M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.79M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.43M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.37M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.54M | – |
See a number that looks wrong?